The ability of tumours to induce new blood-vessel formation has been a major focus of cancer research over the past few decades, and vascular endothelial growth factor (VEGF) is now known to be ...

At about the same time, seminal observations implicating blood-vessel growth in intraocular ... The primary clinical target of our VEGF-specific antibody programs was cancer.

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • NAYA aiming to initiate clinical trials in earl ...

Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract cancer (BTC) is on ...

Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering ... tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors ...

Ottimo Pharma Ltd. is equipped to file an IND and take its lead bifunctional antibody into phase II development, after closing a $140 million series A. The round will accelerate development of ...

Lung cancer, one of the most common and serious ... It is thought that it is caused by vascular endothelial growth factor (VEGF). VEGF is a type of growth factor. Growth factors are chemicals ...

Lung cancer is one of the most common and serious ... It is thought that it is caused by vascular endothelial growth factor (VEGF). VEGF is a type of growth factor. Growth factors are chemicals ...

Clinical trials with BNT327/PM8002 and the PD-(L)1 x VEGF bispecific class of drugs have demonstrated encouraging clinical activity in various tumor types including in patients with PD-L1-low and ...

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase III for Gastric Cancer. According to GlobalData, Phase III drugs for Gastric Cancer have a 46% phase transition ...

SHANGHAI, Dec. 23, 2024 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, ...